Large language models are helping scientists to converse with artificial intelligence and even to generate potential drug targets.
This is a preview of subscription content, log in via an institution to check access.
Change history
02 May 2023
In the version of this article initially published, Andrew Beam’s roles were incorrectly described and have now been updated.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Savage, N. Drug discovery companies are customizing ChatGPT: here’s how. Nat Biotechnol 41, 585–586 (2023). https://doi.org/10.1038/s41587-023-01788-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-023-01788-7
- Springer Nature America, Inc.
This article is cited by
-
A guide to artificial intelligence for cancer researchers
Nature Reviews Cancer (2024)
-
Leveraging generative AI to prioritize drug repurposing candidates for Alzheimer’s disease with real-world clinical validation
npj Digital Medicine (2024)
-
Characterizing emerging companies in computational drug development
Nature Computational Science (2024)
-
Advancing the Production of Clinical Medical Devices Through ChatGPT
Annals of Biomedical Engineering (2024)
-
Innovating Healthcare: The Role of ChatGPT in Streamlining Hospital Workflow in the Future
Annals of Biomedical Engineering (2024)